The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Have you got a receipt for those? Next CEO in share disposal

Thu, 05th Apr 2012 15:31

Lord Wolfson of Aspley Guise, Chief Executive of High Street retailer Next, has made his first sale since March 2007 in a move which triggered a widespread sale of the company's shares. Wolfson, who has stood at the helm of the chain store since 2001, sold off 125,000 shares at 3,057p each for a total of £3.8m shares, taking his stake in the firm down to 0.9%. The share price is now back where it began the week, around the 2,976p mark, having risen above 3,060p before diving to 2,990p on Wednesday morning. The sale was particularly notable because the CEO has only sold shares three times within the last seven years, and consequently sparked fears among investors that the retailer was in trouble. However, Rahul Sharma, Managing Director of retail focused Neev Capital, said he doesn't believe that the sale is "any particular signal to the market," and suggests Wolfson may just have wanted to cash in on the firm's soaring share price. Next's share price is now just 3p down on a week ago, but has gained over 46%, or 946p, in the past year. Top Director BuysSummit Corporation (SUMM) Director name: Mr Glyn EdwardsAmount purchased: 400,000 @ 3.49p Value: £13,960Top Director SellsMood Media Corp. (DI) (MM.) Director name: Mr Justin BeckettAmount sold: 156,400 @ 236.27p Value: £369,526News Corp. 'A' Shares (NCRA) Director name: Mr Stanley S. ShumanAmount sold: 1,073 @ $19.92 Value: $21,374News Corp. 'A' Shares (NCRA) Director name: Mr Lachlan MurdochAmount sold: 1,073 @ $19.92 Value: $21,374News Corp. 'A' Shares (NCRA) Director name: Mr Andrew S B KnightAmount sold: 1,073 @ $19.92 Value: $21,374News Corp. 'A' Shares (NCRA) Director name: Mr Sir Rod EddingtonAmount sold: 1,073 @ $19.92 Value: $21,374News Corp. 'A' Shares (NCRA) Director name: Mr David DeVoeAmount sold: 1,073 @ $19.92 Value: $21,374News Corp. 'A' Shares (NCRA) Director name: Mr Peter BarnesAmount sold: 1,073 @ $19.92 Value: $21,374News Corp. 'A' Shares (NCRA) Director name: Mr Jose Maria AznarAmount sold: 1,073 @ $19.92 Value: $21,374Johnson Service Group (JSG) Director name: Mr Paul OgleAmount sold: 44,880 @ 30.05p Value: £13,486Johnson Service Group (JSG) Director name: Mr Chris SanderAmount sold: 44,880 @ 30.05p Value: £13,486
More News
24 Feb 2020 10:52

Summit Therapeutics Delists In London As Focus Shifts To US

Summit Therapeutics Delists In London As Focus Shifts To US

Read more
24 Jan 2020 12:49

Summit Therapeutics Chief Operating & Medical Officer Roblin Resigns

Summit Therapeutics Chief Operating & Medical Officer Roblin Resigns

Read more
23 Jan 2020 16:47

Summit Gets More Funding For C. Difficile Infection Treatment

Summit Gets More Funding For C. Difficile Infection Treatment

Read more
24 Dec 2019 10:27

Summit Therapeutics Shuffles Board After Raising USD50 Million

Summit Therapeutics Shuffles Board After Raising USD50 Million

Read more
24 Dec 2019 09:09

Summit Therapeutics raises $40m, completes board restructuring

(Sharecast News) - Antibiotic innovation company Summit Therapeutics raised $50.0m on Tuesday by way of a subscription and placing of new ordinary shares and warrants.

Read more
17 Dec 2019 13:20

Summit Therapeutics Reports Decrease In Revenue In Third Quarter

Summit Therapeutics Reports Decrease In Revenue In Third Quarter

Read more
6 Dec 2019 13:34

Summit Therapeutics Plans Wholesale Changes As It Raises Cash

Summit Therapeutics Plans Wholesale Changes As It Raises Cash

Read more
6 Dec 2019 08:56

Summit Therapeutics raising $50m, plans to delist from AIM

(Sharecast News) - Antibiotic innovation company Summit Therapeutics announced a proposed fundraising of about $50m through a subscription and placing of new ordinary shares and warrants to existing investors on Friday, which would be subject to certain shareholder approvals being obtained and certain customary closing conditions being satisfied.

Read more
11 Oct 2019 12:53

Summit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation

Summit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation

Read more
7 Oct 2019 13:23

Summit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff

Summit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff

Read more
3 Oct 2019 14:23

Summit Therapeutics Reports Positive Ridinilazole Trial Results

Summit Therapeutics Reports Positive Ridinilazole Trial Results

Read more
17 Jul 2019 13:48

Summit Therapeutics New Antibiotic Shows Potential Against Gonorrhoea

(Alliance News) - Summit Therapeutics PLC on Wednesday highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat gonorrhoea, at the STI & HIV World Congress in said

Read more
12 Jun 2019 13:54

Summit Therapeutics Narrows First Quarter Loss As Expenses Drop

(Alliance News) - Summit Therapeutics on Wednesday said its loss narrowed in its financial first quarter due to an increase in other operating income and a reduction in operating which develops a

Read more
15 Apr 2019 11:26

Summit Therapeutics DDS-04 Series Antibiotic Cures Infection In Study

LONDON (Alliance News) - Summit Therapeutics PLC on Monday presented proof of concept data for its DDS-04 series of antibiotics targeting Enterobacteriaceae, a family of bacteria that cause severe

Read more
15 Apr 2019 10:16

Summit Therapeutics upbeat on latest DDS-04 data

(Sharecast News) - Antibiotic innovation firm Summit Therapeutics reported on in vivo proof-of-concept data for the DDS-04 series of new mechanism antibiotics targeting enterobacteriaceae on Monday, having presented them at the 29th European Congress of Clinical Microbiology and Infectious Diseases in Amsterdam.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.